EMAIL THIS PAGE TO A FRIEND

Oncotarget

Mutant AKT1-E17K is oncogenic in lung epithelial cells.


PMID 26053093

Abstract

The hotspot E17K mutation in the pleckstrin homology domain of AKT1 occurs in approximately 0.6-2% of human lung cancers. In this manuscript, we sought to determine whether this AKT1 variant is a bona-fide activating mutation and plays a role in the development of lung cancer. Here we report that in immortalized human bronchial epithelial cells (BEAS-2B cells) mutant AKT1-E17K promotes anchorage-dependent and -independent proliferation, increases the ability to migrate, invade as well as to survive and duplicate in stressful conditions, leading to the emergency of cells endowed with the capability to form aggressive tumours at high efficiency. We provide also evidence that the molecular mechanism whereby AKT1-E17K is oncogenic in lung epithelial cells involves phosphorylation and consequent cytoplasmic delocalization of the cyclin-dependent kinase (cdk) inhibitor p27. In agreement with these results, cytoplasmic p27 is preferentially observed in primary NSCLCs with activated AKT and predicts poor survival.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

B5002
5-Bromo-2′-deoxyuridine, ≥99% (HPLC)
C9H11BrN2O5
B9285
5-Bromo-2′-deoxyuridine, BioUltra, ≥99%
C9H11BrN2O5